Compare McKesson Corporation (MCK) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Snap Inc — how do they compare? McKesson Corporation trades at $823.62 (market cap $97.35B), while Snap Inc trades at $4.62 (market cap $7.67B). The key difference: McKesson Corporation is far larger — about 12.7× Snap Inc's market cap, and McKesson Corporation pays a 0.39% dividend while Snap Inc pays none. Which is the better fit depends on your goals.
| MCK | SNAP | |
|---|---|---|
Market Cap | $97.35B | $7.67B |
Sector | Health | Media |
52-Week High | $995.69 | $10.35 |
52-Week Low | $659.01 | $3.93 |
Enterprise Value | $101.98B | $9.05B |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Snap Inc. (SNAP) trades at $4.585, up 1.33% on the day, amid a bearish technical signal and mixed fundamentals. Revenue grew to $5.93 billion in 2025, but the company posted a net loss of $460.49 million, with a negative net margin of -6.72%. Recent news highlights the launch of high-priced AR glasses, which sparked investor concerns and a stock decline. The stock faces resistance near $5, with analyst consensus price target at $5.75, suggesting modest upside potential from current levels.
The outlook remains cautious; while cost-cutting and AR innovation offer long-term growth avenues, persistent losses, competitive pressures, and high debt levels pose significant risks. Investor sentiment is divided, with analysts mostly neutral to bullish, but the stock's performance hinges on achieving profitability and successful monetization of new initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
